Introduction
cytotoxic drugs may be attributable to resistance to apoptosis [7] . Several strategies for overcoming the apoptotic resistance of neoplastic populations have been developed and hold potential therapeutic value, and many new approaches to the treatment of pancreatic adenocarcinoma are currently being investigated [5, 8] . Several approaches focus on combination therapies in which gemicitabine is combined with a second cytotoxic agent (e.g. auristatin-PE) [9] or on targeted biological therapy (e.g. [10] [11] [12] .
OSI-774/Tarceva and the anti-Epidermal growth factor receptor (EGFR) antibody C225)
Polo-like kinase 1 (Plk-1), a mitotic cyclin-independent serinethreonine kinase, is a member of the family of polo-like kinases involved in a wide variety of cell cycle processes. Polo-like kinase was first identified in Drosophila melanogaster, where mutants display abnormal mitotic and meiotic divisions caused by failure to properly organize the mitotic spindle [13] . In mammalian cells, Plk-1 is primarily localized at the centrosome, where it is responsible for centrosome separation and maturation [14] . Plk-1-specific antibodies introduced into HeLa cells by microinjection prevent centrosome separation and reduce ␥-tubulin accumulation [14] . In addition to its role in regulating centrosome function, Plk-1 is involved in the timing of mitotic entry and exit [15] and is one of the most important regulators of mitotic progression in mammalian cells [16] . It has been implicated in the targeting of cyclin B1 to the nucleus during prophase [17] , the activation of Cdc25C phosphatase [18] , and the inactivation of the Cdk1-cyclin B complex required for mitotic exit [15] . Plk-1 is also a target of the G2 DNA damage checkpoint, where it undergoes ubiquitin-dependent proteolysis mediated by the checkpoint protein Chfr; this implicates the loss of Plk-1 function as an important response to DNA damage during the G2 phase of the cell cycle [19] .
The elevation of Plk-1 expression occurs in a broad range of human tumours [20] [21] [22] [23] . The activity of Plk-1 is elevated in tissues and cells with a high mitotic index, including cancer cells [24, 25] , and a close correlation between mammalian Plk-1 expression and carcinogenesis has recently been documented. Overexpression of the Plk-1 gene has been found in pancreatic cancer cell lines and neoplastic tissues [26] . It has recently shown that its overexpression has been identified as a common and early event in pancreatic cancer progression [27] , and the depletion of Plk-1 by small interfering RNA (siRNA) has been shown to dramatically inhibit cell growth and induce apoptosis in vitro [28, 29] . Furthermore, constitutive expression of Plk-1 in NIH3T3 cells causes oncogenic focus formation and induces tumour growth in nude mice [30] . Taken together, these observations suggest that Plk-1 is an important player in cell growth and proliferation and may be a potential target for cancer therapy.
RNA interference (RNAi) is emerging as a strategy for highly specific post-transcriptional suppression of gene expression, both in vitro and, more recently, in vivo [31] [32] [33] [34] [35] . It has been shown that siRNAs targeting the M2 subunit of ribonucleotide reductase exhibit therapeutic synergism with gemcitabine, resulting in the retardation of tumour growth, the reduction of tumour mass by 87%, and the absence of hepatic metastasis in a nude mouse xenograft model [36, 37] . The 
Materials and methods

Construction of vectors and design of siRNAs
Cell survival assay and synergistic analysis
Cell viability was measured using a 3-bis-(2-methoxy-4-nitro-5-sulfenyl)-(2H)-tetrazolium-5-carboxanilide (MTT) assay (Cell Proliferation kit, Roche
Molecular Biochemicals, Indianapolis, IN, USA), as described previously [39] . (Fig. 3) . The target specificity of Plk-1 siRNA was verified by using an anti-Plk-2 antibody, our results clearly revealed that Plk-1 siRNA did not change the level of Plk-2 protein in the three pancreatic tumour cell lines (Fig. 4) (Figs. 5 and 6 ). In Plk1-siRNA vector transfected AsPC-1 (Fig. 5A), PANC1 (Fig. 5B) , and BxPC3 cells (Fig. 5C) (Fig. 6A), PANC1 (Fig. 6B) , and BxPC3 (Fig. 6C) (Fig. 5D and Fig. 6D) (Fig. 8, panel 3) . (Fig. 8, panel 4) . Not surprisingly, the combination treatment with pBS/U6-Plk-1-siRNA and gemcitabine did not enhance apoptosis induction in the normal pancreas epithelial cell line HPDE6c7 (Fig. 8, bottom row) [42] . Human Plk1-deficient cells are unable to separate their centrosomes, fail to form a bipolar spindle, and undergo a Mad2/BubR1-dependent prometaphase arrest [43] . Using RNAi, Liu et al. [44] [29, 31-32, 38, 44, 47] has led to many attempts to explore this methodology in potential therapeutic settings [47] .
Cell cycle and apoptosis analysis by flow cytometry
Statistical analysis of data
Differences between treatments with Plk-1 siRNAs and control siRNAs were analysed using a one-tailed or two-tailed paired t-test for the cell survival assays and cell cycle and apoptosis studies (Statview for PC
Effect of combination treatment with Plk-1 siRNA and gemcitabine on cytotoxicity in pancreatic cancer cells in vitro
Given that Plk-1 siRNA has suppressive effects on cell cycle progression and cell proliferation in our cell systems, we next tested the potential application of Plk-1 siRNA for sensitizing pancreatic adenocarcinoma cells to gemcitabine. The effect of combined Plk-1 siRNA and gemcitabine therapy on the experimental pancreatic tumour cells was evaluated in vitro. The cells were first transfected with pBS/U6-Plk-1 and then exposed to gemcitabine at various concentrations. Empty pBS/U6 vector was used as a vector control, and cells treated with PBS were used as the mock control. Cell viability was determined for up to 4 days after treatment, using an MTT assay. Even at the lower doses of both agents, the combination of pBS/U6-Plk-1 plus gemcitabine was significantly more effective in killing cells than either pBS/U6-Plk-1 or gemcitabine alone (Fig. 7A). To further evaluate the interaction between Plk-1 gene therapy and gemcitabine chemotherapy, we determined the CI, which demonstrated a strong synergistic anti-tumour activity at the lower doses of the Plk-1-expressing construct (0.25-0.5 ng/ml) and gemcitabine (0.5-1 nM) in AsPC-1, PANC1, and BxPC3 cells (Fig. 7B-D).
Enhancement of gemcitabine-induced apoptosis by Plk-1 siRNA in pancreatic cancer cells
Finally, we determined the effect of combined Plk-1 siRNA and gemcitabine treatment on the induction of apoptosis in our three cell models. Each pancreatic tumour cell line was treated with pBS/U6-Plk-1 at a dose of 0.5 ng/ml or gemcitabine at a concentration of 0.1 nM, or a combination of the two. Apoptotic cell death was detected by fluorescence-activated cell sorting (FACS) analysis of sub-G1 cells at 48 hrs after the drug treatment. Compared with the cells treated with PBS, pBS/U6, gemcitabine, or pBS/U6-Plk1-siRNA alone, the three pancreatic cancer cell lines treated with the combination of pBS/U6-Plk-1-siRNA and gemcitabine had a dramatically increased population of apoptotic cells (Fig. 8). The combination of Plk-1 siRNA and gemcitabine increased the frequencies of apoptosis in the AsPC-1, PANC1, and BxPC3 pancreatic cancer cell lines from 11, 16 and 15% to 33, 38 and 43% (Fig. 8, panel 5), respectively, compared with the frequencies in the cells treated with gemcitabine as a single agent
Moreover, the control vector pBS/U6 did not increase gemcitabine-induced cell death in our model systems
In the present study, we sought to address the possibility of using Plk-1 [18, 48] and mediate nuclear translocation of Cdc25C [49] , which leads to the activation of Cdc2 (Cdk-1) protein kinase activity. Plk-1 can also activate Cdc2 through the stabilization of cyclin B [50] or the degradation of Wee1 [42] and by participating in a positive 
